Make your one-time, tribute, or recurring online gift to support brain tumour patient programs and research today: Donate
What is Avastin?
Avastin® (Bevacizumab) is the first and only biologic treatment approved by Health Canada for recurrent glioblastoma multiforme (GBM), which offers an additional treatment option for people with the disease.
How is Avastin administered?
Avastin is given as a single agent at 10 mg/kg intravenously, once every two weeks.
How does Avastin work?
Avastin directly targets the tumour by controlling its growth and extends survival with only a limited impact on quality of life.
Is Avastin approved by Health Canada?
Health Canada approved Avastin in March 2010 as treatment for recurrent GBM.
How do patients access Avastin?
The answer to this question depends on:
Beyond the provinces where there is provincial coverage, access to Avastin depends on the type of private insurance coverage each patient may have (often from an employer). Once prescribed Avastin by their oncologist, a patient will contact their insurance carrier to determine coverage.
Please note, however, reimbursement via private insurance coverage is often granted on a case-by-case basis and may not be guaranteed.
There is also a Roche Patient Assistance Program (RPAP) in place to help patients access Avastin.
How do patients connect with the RPAP program?
For reimbursement navigation and coordination, financial assistance and infusion support services, patients should work with their oncologist to enrol in RPAP or call the program directly, toll-free, at 1-888-748-8926, Monday to Friday, 8:00 am to 8:00 pm Eastern Standard Time. Patients can also visit the RPAP website for more information.
Find more information about how to access Avastin
What is the most recent information about Avastin?
New research about the brain tumour treatment Bevacizumab (Avastin®) was released at the recent American Society of Clinical Oncology (ASCO) 2013 Annual Meeting. Results were presented from two recent clinical trials focused on the treatment. Read our summary of the results.
Return to Information Sheets here.
This information is provided for information purposes only, and do not represent advice, an endorsement or a recommendation, with respect to any product, service or business, and/or the claims and properties thereof, by Brain Tumour Foundation of Canada. Always consult your health care team if you have questions about your medical care and treatments options.
Read why Katherine is now "filled with gratitude" despite a diagnosis of Anaplastic-Ependymoma, stage 3 brain cancer, at the age of twelve. It's been a long determined journey for her. Read her story, in her wordsLearn more
When John Hatcher laces up his running shoes on Saturday, October 2, 2016 he joins over a dozen of his family members and friends for...Learn more
This colourful book tells the story of a little girl and her journey with a brain tumour...Learn more